Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Lymphoma Clinical Trial

Official title:

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03489369
• Other study ID #: Sym022-01
• Status: Completed
• Phase: Phase 1
• Start date: May 8, 2018
• Est. completion date: January 6, 2020

Study information

• Verified date: February 2021
• Source: Symphogen A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Description:

This study will evaluate the preliminary safety, tolerability, and dose-limiting toxicities (DLTs) of Sym022, an anti-lymphocyte activation gene 3 (anti-LAG-3) monoclonal antibody (mAb). The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of Sym022 when administered once every 2 weeks (Q2W) by intravenous (IV) infusion to patient cohorts with locally advanced/ unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available. If an MTD is not identified, a maximum administered dose (MAD) will be determined. Sym022 will be given to patients in escalating dose cohorts; each patient will be given one fixed dose level.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 6, 2020
• Est. primary completion date: January 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients, = 18 years of age at the time of obtaining informed consent.

• Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.

• Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.

• Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.

• Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

• Not of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.

Exclusion Criteria:

• Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a highly effective method of contraception.

• Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.

• Hematologic malignancies other than lymphomas.

• Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable

• Active uncontrolled bleeding or a known bleeding diathesis

• Clinically significant cardiovascular disease or condition

• Significant pulmonary disease or condition

• Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.

• An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive medications.

• History of organ transplantation (e.g. stem cell or solid organ transplant)

• History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy

• Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy, with exceptions.

• Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.

• Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).

• Other Inhibitors of LAG-3

• Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to first administration of study drug and during study

• Any other investigational treatments within 4 weeks prior to and during study

• Radiotherapy for target lesions within 4 weeks prior to first administration of study drug unless PD has been documented in the lesion following treatment, and during study.

• Radiotherapy for non-target lesions within 1 week prior to first administration of study drug

• Immunosuppressive or systemic hormonal therapy

• Prophylactic use of hematopoietic growth factors within 1 week prior to first administration of study drug and during Cycle 1 of study

Related Conditions & MeSH terms

• Lymphoma
• Metastatic Cancer
• Solid Tumor

Intervention

Drug:
• Sym022
Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
United States	South Texas Accelerated Research Therapeutics (START) Midwest	Grand Rapids	Michigan
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Symphogen A/S

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of Treatment Related Adverse Events (AEs).	Assess the safety, tolerability and dose-limiting toxicities of Sym022 on a Q2W schedule to establish the MTD and/or RP2D.	19 months
Secondary	Evaluation of the Immunogenicity of Sym022.	Serum sampling and incidence (%) per dose level to assess the potential for anti-drug antibody (ADA) formation. Count of participants show the number of participants who were tested positive for anti-Sym022 ADA.	19 months
Secondary	Evaluation of Objective Response (OR) or Stable Disease (SD).	Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017), or Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST), depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.	13 months
Secondary	Time to Progression (TTP) of Disease.	Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.	13 months
Secondary	Area Under the Concentration-time Curve in a Dosing Interval (AUC).	Will be estimated using non-compartmental methods and actual timepoints.	19 months
Secondary	Maximum Concentration (Cmax)	Will be derived from observed data.	0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
Secondary	Time to Reach Maximum Concentration (Tmax)	Will be derived from observed data.	0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
Secondary	Trough Concentration (Ctrough)	Will be derived from observed data.	0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
Secondary	Terminal Elimination Half-life (T½)	Will be estimated using non-compartmental methods and actual timepoints.	0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
Secondary	Clearance (CL)	Will be estimated using non-compartmental methods and actual timepoints.	0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)